loading

Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie

pulisher
Jul 26, 2025

Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating - MSN

Jul 26, 2025
pulisher
Jul 25, 2025

Is Neurocrine Biosciences Inc. stock overhyped or has real potentialExponential wealth increase - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

10 Best Strong Buy Healthcare Stocks to Buy Now - Insider Monkey

Jul 25, 2025
pulisher
Jul 25, 2025

Is Neurocrine Biosciences Inc. a good long term investmentRecord-breaking gains - Autocar Professional

Jul 25, 2025
pulisher
Jul 24, 2025

Neurocrine Biosciences (NASDAQ:NBIX) Earns Buy Rating from Analysts at Truist Financial - MarketBeat

Jul 24, 2025
pulisher
Jul 24, 2025

11 Best Long Term Low Risk Stocks to Invest in - Insider Monkey

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Neurocrine Biosciences Inc. stockDynamic investment opportunities - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

Jul 23, 2025
pulisher
Jul 23, 2025

Neurocrine Bio. stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Canada

Jul 23, 2025
pulisher
Jul 22, 2025

What drives Neurocrine Biosciences Inc. stock priceRapidly growing investment returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Neurocrine Biosciences Inc. Stock Analysis and ForecastExponential wealth increase - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Truist Securities Initiates Coverage of Neurocrine Biosciences (NBIX) with Buy Recommendation - MSN

Jul 21, 2025
pulisher
Jul 21, 2025

Lobbying Update: $890,000 of NEUROCRINE BIOSCIENCES INC lobbying was just disclosed - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Truist Securities initiates Neurocrine Bio stock with Buy rating on Crenessity potential - Investing.com Canada

Jul 21, 2025
pulisher
Jul 18, 2025

Daily Turnover | The turnover of Neurocrine Biosciences on 7/18 was $100.31 Million, Ranking 820 - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Stock Performance Influenced By Its Fundamentals In Any Way? - simplywall.st

Jul 18, 2025
pulisher
Jul 17, 2025

Neurocrine Biosciences’ NBI-921352 Study: A Potential Game-Changer for SCN8A-DEE Treatment - TipRanks

Jul 17, 2025
pulisher
Jul 16, 2025

Lobbying Update: $80,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed - Nasdaq

Jul 16, 2025
pulisher
Jul 16, 2025

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach - GlobeNewswire Inc.

Jul 16, 2025
pulisher
Jul 16, 2025

Neurocrine reports positive results from Crenessity trial - MSN

Jul 16, 2025
pulisher
Jul 15, 2025

Neurocrine Biosciences shares rise 2.09% after-hours after presenting new analysis on CAH treatment. - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Neurocrine shares new one-year data from trial of Crenessity for CAH - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Groundbreaking AI Research Exposes Lifelong Treatment Challenges for Rare CAH Patients - Stock Titan

Jul 15, 2025
pulisher
Jul 15, 2025

Neurocrine shares registry data showing CAH treatment challenges - StreetInsider

Jul 15, 2025
pulisher
Jul 15, 2025

Neurocrine Biosciences Presents New Analysis of CAHtalog® Registry Showing Most Patients with Classic Congenital Adrenal Hyperplasia Experienced High Glucocorticoid Exposure, Suboptimal Disease Control or Both at ENDO 2025 - PR Newswire

Jul 15, 2025
pulisher
Jul 15, 2025

New weight reduction data for Crenessity presented by Neurocrine - The Pharma Letter

Jul 15, 2025
pulisher
Jul 15, 2025

Wedbush Raises Price Target on Neurocrine Biosciences to $137 From $130, Keeps Outperform Rating - MarketScreener

Jul 15, 2025
pulisher
Jul 14, 2025

What makes Neurocrine Biosciences Inc. stock price move sharplyMassive Upside Selection - beatles.ru

Jul 14, 2025
pulisher
Jul 14, 2025

NBIX : Phase 3 Study Shows CRENESSITY Improves Weight-Related Outcomes In Adrenal Disorder Patients - Nasdaq

Jul 14, 2025
pulisher
Jul 14, 2025

Endometriosis Market to Reach New Heights in Growth by 2034, - openPR.com

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine Biosciences CRENESSITY Shows Clinically Meaningful Weight Loss And Insulin Resistance Improvement In Adults And Children With CAH In Phase 3 Trials, Presented At ENDO 2025 - 富途牛牛

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine presents one-year data showing weight improvements with CRENESSITY - StreetInsider

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting - Eastern Progress

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine presents one-year CRENESSITY data at ENDO 2025 conference - StreetInsider

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine Biosciences Reports Positive 1-year Data Of Crenessity In Adults With CAH At ENDO 2025 - Nasdaq

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine Biosciences: CRENESSITY's Breakthrough in CAH Positions NBIX for Sustained Growth - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Neurocrine reports positive results from Crenessity trial (NBIX) - Seeking Alpha

Jul 14, 2025
$304.50
price down icon 0.62%
drug_manufacturers_specialty_generic RDY
$14.67
price down icon 0.27%
$9.41
price up icon 0.64%
$14.92
price up icon 1.57%
$16.54
price up icon 1.29%
Capitalizzazione:     |  Volume (24 ore):